Tag: Emcure Pharma

Emcure Pharmaceuticals is aiming to be among the top five drug firms in the country in the next five to seven years as it also eyes acquisitions for growth going... Read More

Emcure Pharma: The leading pharma company is expected to float an IPO of Rs. 4500-5000 crore IPO . The initial public offering (IPO) comprises fresh issuance of equity shares worth... Read More

Amidst the raging second wave of the COVID-19 pandemic and many fearing a third wave, the healthcare sector is in the limelight for the second consecutive year as several pharma... Read More

Pune-based Emcure Pharmaceuticals Ltd is making its second attempt to float an initial public offering (IPO), joining a bunch of healthcare companies to tap into the stock market buoyancy. Emcure... Read More

Speaking at the 76th session of the UN General Assembly last month, Prime Minister Narendra Modi said: “India has developed the world’s first DNA vaccine. An m-RNA vaccine is in the... Read More

Emcure Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Pune, Maharashtra. Emcure's product portfolio includes tablets, capsules (both Softgel capsules and hard-gel capsules) and injectables. Emcure is planning to raise... Read More

Emcure Pharmaceuticals Limited is a Non-govt company, incorporated on 16 Apr, 1981. It's a public unlisted company and is classified as'company limited by shares'. Company's authorized capital stands at Rs 20000.0... Read More

Emcure is growing pharma company with good future projects and provides overall opportunities for both professional and personal development. Strong growth in generic business,oncology and domestic business is strong. Pros Good working culture,... Read More

Emcure Pharmaceuticals Ltd. has a diversified revenue profile, with 44% revenue from India, 31% from U.S./Canada, and 12% from Europe. Apart from an established market position (ranked 12th) in IPM,... Read More

Pune-based Gennova Biopharmaceuticals has revealed that its mRNA vaccine for COVID-19 is being continuously peer reviewed and is optimistic of launching it before the end of this year. Gennova's HGCO19 is... Read More